1. Introduction {#sec1}
===============

In-feed supplementation of antibiotics was firstly reported to promote growth in chickens ([@bib79]) and subsequently in pigs ([@bib51], [@bib68]). Since then, antibiotics have been routinely used in livestock production at subtherapeutic levels for disease prevention and growth promotion and are more commonly known as antibiotic growth promoters ([@bib22]). Unfortunately, continuous long-term exposure of gut commensals and pathogens to low-dose antibiotics in livestock animals has been linked to increased emergence of antibiotic-resistant pathogens ([@bib22], [@bib62], [@bib126]). Consequently, the European Union has banned the use of all antibiotics for the purpose of growth promotion since January 2006 ([@bib112]), and the United States has taken a similar measure to phase out the application of medically important antibiotics for livestock production starting January 2017. A shift in governmental policy and public opinion has resulted in an urgent need for alternatives to in-feed antibiotics in order to ensure animal health and production efficiency with a minimum risk of triggering antimicrobial resistance.

Antibiotic alternatives such as organic acids, probiotics, prebiotics, and essential oils have been used for decades, but with limited success ([@bib112], [@bib116]). More effective antibiotic alternatives are, therefore, needed. Host defense peptides (HDP), also known as antimicrobial peptides, possess direct antimicrobial, immunomodulatory and often barrier protective activities ([@bib44], [@bib47], [@bib72], [@bib95]). A great majority of these HDP are expressed by mucosal epithelial cells of the digestive, respiratory, and urogenital tracts ([@bib70]). The strategies to increase HDP accumulation on mucosal surfaces will conceivably enhance animal immunity, health and disease resistance without relying on antibiotics. Consistently, accumulating evidence suggests the potential for HDP to be developed as novel antibiotic alternatives ([@bib99], [@bib95], [@bib137], [@bib130]). While dietary supplementation of exogenous HDP have shown promise in swine and chickens ([@bib137], [@bib130]), modulation of endogenous HDP to ensure animal growth and immunity is just beginning to be explored, with multiple compounds being identified with the ability to induce endogenous HDP synthesis ([@bib10], [@bib128], [@bib70]). The goal of this review is to summarize the relevant work regarding induction of HDP by dietary compounds, focusing specifically on butyrate and vitamin D.

2. Host defense peptides as effectors of innate immunity {#sec2}
========================================================

2.1. Classification of HDP {#sec2.1}
--------------------------

Host defense peptides consist of a large group of diverse small peptides with direct microbicidal activities that exist in virtually all species of life and constitute an important mechanism of the first-line defense ([@bib72]). In vertebrates, a majority of HDP belong to either the defensin or cathelicidin family. Members of the defensin family contain 3 conserved disulfide bridges that form 2-3 antiparallel β-sheets ([@bib113]). Based upon the explicit spacing pattern of the cysteine residues, defensins are further categorized into α-, β-, and θ-defensins. While θ-defensins have only been found in primates, β-defensins are present in virtually all vertebrate animals, with only certain mammalian species harboring α-defensins ([@bib113]). Mammalian β-defensin genes are located in several separate clusters on different chromosomes, with the α- and θ-defensin genes, if any, existing within one of the β-defensin clusters ([@bib84], [@bib85]). The human genome harbors 6 functional α-defensins and 5 pseudogenes in one cluster, 39 β-defensins in 5 different clusters, and one θ-defensin pseudogene ([@bib109], [@bib84], [@bib85]). On the other hand, at least 29 β-defensins are clustered on 4 different chromosomes in pigs ([@bib13]), whereas the bovine genome encodes a minimum of 57 β-defensins in 4 separate clusters ([@bib74]). In chickens, a total of 14 β-defensin genes are located in tandem in a single cluster ([@bib139], [@bib69]).

Cathelicidins are identified by the presence of a highly conserved cathelin domain that is cleaved off to release a biologically active, mature peptide with diverse sequences ([@bib147]). The human genome only contains one cathelicidin gene, known as human cationic antimicrobial peptide -18 (*hCAP-18*), cyclic Adenosine monophosphate (*CAMP*) or *LL-37* ([@bib37]). Four cathelicidin genes have been identified in chickens, namely fowlicidins 1-3 (or *CATH1-3*) ([@bib138]) and cathelicidin-B1 ([@bib33]) while 10 cathelicidin genes have been reported in cattle ([@bib134]) and 11 cathelicidin genes in pigs ([@bib100]).

Defensins, and β-defensins in particular, are expressed in epithelial and phagocytic cells in a variety of different tissues, primarily on the mucosal surfaces lining the gastrointestinal, respiratory, and urogenital tracts along with the skin ([@bib113]). Cathelicidins are also present in various epithelial cells, but with more abundant expression in mammalian neutrophils ([@bib113]) or avian heterophils ([@bib16], [@bib150]). Additionally, chicken cathelicidin-B1 is expressed in the M cells of the bursa of Fabricius ([@bib33]).

2.2. Pleiotropic effects of HDP {#sec2.2}
-------------------------------

Host defense peptides are characterized by their direct antimicrobial activities against a range of pathogens. Cathelicidins and β-defensins are active against Gram-negative and Gram-positive bacteria along with certain viruses, fungi, and protozoa ([@bib148], [@bib122], [@bib129]). Host defense peptides are generally positively charged and amphipathic enabling them to bind to negatively charged phospholipids on bacterial membranes through physical electrostatic interactions. Once bound, hydrophobic regions of the HDP are inserted into the membrane bilayers to form pores mainly through 'barrel-stave', 'carpet' or 'toroidal-pore' mechanisms ([@bib9], [@bib122]). Certain HDP such as human α-defensin human neutrophil peptides-1 (HNP-1) and porcine cathelicidin prolinearginine rich-39 (PR-39) are also able to enter the bacterial cells and interfere with DNA and protein synthesis, protein folding, or cell wall synthesis ([@bib9]). These modes of action make it extremely difficult for bacteria to develop resistance to HDP even through millions of years of co-evolution, although certain bacteria are able to resist HDP killing by reducing the negative charge on the membrane ([@bib86]). This is exemplified by the ability of *Salmonella enterica* and *Pseudomonas aeruginosa* to reduce their membrane affinity for HDP by incorporating positively charged aminoarabinose into lipid A ([@bib26], [@bib77]).

Besides the antimicrobial activities, HDP possess profound immunomodulatory and barrier protective functions as well. Many HDP are chemotactic to neutrophils (or heterophils in chickens), monocytes, lymphocytes, or dendritic cells, with the ability to further activate macrophages and dendritic cells ([@bib47], [@bib72]). Chicken CATH-1 has the capacity to recruit neutrophils and activate macrophages in mice ([@bib8]), while protecting mice from infection ([@bib7], [@bib8]). Three bovine β-defensins were also found to be chemotactic to immature dendritic cells ([@bib71]). Several, but not all human defensins, were recently shown to have mucosal barrier protective properties by directly upregulating mucin and tight junction protein expression ([@bib95]). Porcine cathelicidin PR-39 is also capable of improving angiogenesis and wound repair with the ability to suppress nicotinamide adenine dinucleotide phosphate (NADPH) oxidase assembly and activation ([@bib31], [@bib114]).

2.3. Impact of exogenous HDP on growth and disease prevention {#sec2.3}
-------------------------------------------------------------

Consistent with their antimicrobial, immunomodulatory, and barrier protective activities, dietary supplementation of synthetic or recombinant HDP has been found to enhance animal growth and gut health, particularly in the context of disease ([@bib137]), highlighting the potential of HDP to be developed as antibiotic alternatives for disease control and prevention. Weanling pigs challenged with enterotoxic *Escherichia coli* show an improvement in growth performance with a decrease in the incidence of diarrhea when supplemented with colicin E1 (a bacteriocin) ([@bib17]), recombinant cecropin A/D (a silkworm HDP) ([@bib136]), recombinant lactoferrin (a bovine HDP) ([@bib123]), or a mixture of three recombinant HDP ([@bib141]). In healthy piglets, presence of a synthetic HDP is also capable of improving growth performance along with intestinal morphology and digestibility ([@bib146]). Similar results have also been observed in broilers. Dietary inclusion of a synthetic HDP or recombinant cecropin A/D resulted in enhanced growth performance associated with improved intestinal morphology and nutrient digestibility ([@bib132], [@bib14], [@bib15]).

Although direct feeding of synthetic or recombinant HDP show their potential to be used as antibiotic alternatives, this approach is not expected to be efficient as a majority of exogenous HDP would be digested in the stomach and upper intestinal tract without efficiently reaching the lower intestinal tract where most pathogens reside. Moreover, it remains unclear whether this strategy is cost-effective and commercially viable for livestock applications as the cost of producing synthetic or recombinant HDP is expected to be substantial. Instead, dietary modulation of the synthesis of endogenous HDP may be a better approach. Currently, a range of small-molecule compounds have been found to induce HDP synthesis in humans and livestock animals ([@bib10], [@bib128], [@bib70], [@bib143]). Of these compounds, butyrate and vitamin D are among the earliest identified and most potent, so they will be the focus of this review.

3. Butyrate {#sec3}
===========

3.1. Physiological roles of butyrate {#sec3.1}
------------------------------------

Short-chain fatty acids (SCFA) are a group of fatty acids consisting of less than 6 carbons that are produced by bacterial fermentation of non-digestible carbohydrates in the large intestine of animals as well as the rumen of ruminant animals ([@bib42], [@bib11]). Acetate, propionate, and butyrate are the primary SCFA produced, with acetate comprising the greatest percentage. Butyrate encompasses the smallest percentage of SCFA produced, but is the primary energy source for colonocytes in humans ([@bib11]). The amount of butyrate produced through bacterial fermentation varies greatly with animal species, age, gastrointestinal location, and diet ([@bib92]). In chickens, for a typical corn and soybean meal diet, the butyrate concentration in small intestine (duodenum, jejunum, and ileum) is typically 0.1 to 0.2 mmol/L of the digesta, while it can reach 7 to 17 mmol/L in the cecum, depending upon the bird age ([@bib92]). In weanling pigs, butyrate concentrations in the jejunum, ileum, and cecum was reported to be 2.2, 2.8, and 10.4 mmol/L of the digesta, respectively ([@bib28]). In cattle, butyrate amounts to 10 to 15 mmol/L in the rumen fluid ([@bib3]). Short-chain fatty acids produced in the large intestine are estimated to contribute 5% to 15% of the total caloric requirements of humans ([@bib4]), while providing approximately 24% of the energy for heat production in pigs ([@bib144]). Short-chain fatty acids production in the cecum of steers provides approximately 8% of metabolizable energy, while ruminal SCFA contribute 50% to 75% ([@bib115]).

Apart from being an important energy source for the intestinal cells, SCFA and butyrate in particular exert a range of mucosal protective effects by suppressing carcinogenesis, inflammation, and barrier permeability ([@bib42], [@bib11]). Butyrate is capable of preventing colorectal cancers through inhibition of tumor proliferation, stimulation of differentiation, and induction of apoptosis in cancerous cells ([@bib106], [@bib11]). Paradoxically, butyrate stimulates cell proliferation and differentiation while inhibiting apoptosis in normal intestinal cells in humans, cattle, and pigs ([@bib106], [@bib57], [@bib73], [@bib38]). Butyrate promotes intestinal barrier function by facilitating tight junction assembly and inducing the expression and synthesis of multiple tight junction proteins and mucin-2 ([@bib87]). Moreover, butyrate displays potent anti-inflammatory effects through suppression of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-12, and tumor necrosis factor-α (TNF-α) ([@bib98], [@bib80], [@bib29]), while inducing anti-inflammatory cytokine, IL-10, in humans ([@bib98]). In chickens, butyrate has a minimum effect on the expression of IL-1β, IL-6, interferon-γ (IFN- γ) or nitric oxide, but suppresses the induction of these cytokines by lipopolysaccharides (LPS) both *in vitro* and *in vivo* ([@bib118], [@bib152], [@bib155]). Similarly, dietary supplementation of weanling pigs with sodium butyrate reduces serum levels of IL-6 and TNF-α ([@bib133]).

3.2. Role of butyrate in gut health and animal performance {#sec3.2}
----------------------------------------------------------

Consistent with a plethora of beneficial effects of butyrate, an improvement in animal health and performance is often observed following butyrate supplementation. Intestinal morphology of broilers fed 0.5, 1 or 2 g/kg of unprotected sodium butyrate shows an increased villus height to crypt depth ratio ([@bib48]), while oral gavage of sodium butyrate at 3 g/kg of the daily intake of milk dry matter during the suckling phase improves apparent digestibility of dry matter, organic matter, and nitrogen of growing pigs ([@bib59]). Inclusion of 2 g/kg sodium butyrate in calf milk replacer or starter diets stimulates rumen development resulting in increased dry matter intake, metabolizable energy, and crude protein intake along with a decrease in the incidence of scours ([@bib35]). Multiple studies have reported improved growth performance, particularly in the context of infections, in broilers when supplemented with 4 g/kg butyrate glycerides or 1 g/kg sodium butyrate ([@bib61], [@bib152]). Similarly, the growth performance of growing and weanling pigs were also improved when fed 1.7 or 2 g/kg sodium butyrate ([@bib30], [@bib140]). This is also the case in dairy calves when supplemented with 3 g/kg of dry matter or 2 g/kg of the diet ([@bib39], [@bib35]). However, butyrate supplementation appears to provide no obvious benefits in growth performance in healthy animals ([@bib61], [@bib5], [@bib38], [@bib152], [@bib27]).

4. Role of butyrate in HDP expression {#sec4}
=====================================

In addition to the positive effects of butyrate on energy supply, inflammation, barrier integrity, and gut health, recent research has indicated the ability of butyrate to modulate intestinal immunity through induction of endogenous HDP in humans and multiple livestock species.

4.1. Humans {#sec4.1}
-----------

Butyrate is capable of enhancing LL-37 transcription and translation in a time- and dose-dependent manner in a variety of human cell lines ([@bib46], [@bib105], [@bib103]). In addition to butyrate, other SCFA and their structural analogs such as propionate, isobutyrate, and 4-phenylbutyrate are also capable of stimulating LL-37 synthesis in human cells ([@bib105], [@bib117]). A direct comparison of saturated free fatty acids for their HDP-inducing activity revealed that fatty acids with 4-6 carbons are the most potent ([@bib50]). Consistently, oral administration of sodium butyrate or 4-phenylbutyrate reverses *Shigella*-mediated downregulation of cathelicidin in rabbits ([@bib89], [@bib101]). Furthermore, an enema of sodium butyrate (80 mmol/L), twice daily for 3 days, increased both *LL-37* mRNA levels in the rectal epithelia and LL-37 protein concentrations in the stools of human shigellosis patients ([@bib90]).

Besides LL-37, human β-defensin 1 (HBD-1) and HBD-2 are also induced by butyrate, albeit in a cell type- and gene-specific manner ([@bib102], [@bib110]). For example, butyrate shows a minimum effect on the expression of HBD-1 and HBD-2 in primary human keratinocytes, but enhances strongly the expression of both defensins in HT-29 colonic epithelial cells, with preferential induction of HBD-2, but not HBD-1, in U937 monocytes ([@bib102]).

4.2. Poultry {#sec4.2}
------------

In chickens, 1 to 4 mmol/L sodium butyrate increases the expression of multiple, but not all, HDP in different cell types, showing a clear gene- and cell type-specific induction pattern ([@bib118]). Among all 14 chicken β-defensins and cathelicidins, 6 β-defensins (AvBD3, AvBD4, AvBD8, AvBD9, AvBD10, and AvBD14) and 1 cathelicidin (CATH-B1) are induced to different extents, with AvBD9 showing the highest magnitude of induction. Among several chicken cell types examined, butyrate increased *AvBD9* gene expression by thousands, hundreds, and tens of times in HD11 macrophage cells, primary monocytes, and intestinal explants, respectively ([@bib118]). Despite an inability to detect the HDP protein expression levels due to a lack of specific antibodies, an increase in the bacterial killing activity of chicken monocytes has been observed following butyrate treatment, which is very likely to be mediated through HDP induction as butyrate at the concentrations used has neither a direct antimicrobial activity nor the capacity to increase oxidative burst or phagocytosis of monocytes ([@bib118]). Consistently, dietary supplementation of 1 or 2 g/kg of sodium butyrate augments *AvBD9* expression throughout the intestinal tract of chickens and the clearance of *Salmonella enteritidis* following an experimental infection ([@bib118]). Among short-, medium-, and long-chain fatty acids, SCFA are the most potent, with butyrate giving the highest fold induction ([@bib119]). Several butyrate analogs such as benzyl butyrate and glyceryl tributyrate also display an ability to increase *AvBD9* expression, albeit at a lesser magnitude ([@bib120]).

4.3. Cattle {#sec4.3}
-----------

In cattle, studies with mammary epithelial cells have demonstrated the ability of 0.25, 0.5, 1 mmol/L butyrate, 1 mmol/L propionate, and 1 mmol/L hexanoate to reduce *Staphylococcus aureus* internalization by 50% to 60% ([@bib82], [@bib2]). Stimulation of mammary epithelial cells with sodium butyrate followed by *S. aureus* infection showed a significant increase in bovine β-defensin and tracheal antimicrobial peptide (*TAP*) expression. Increased *HDP* expression was seen with 0.5 mmol/L butyrate which was associated with the greatest inhibition of *S. aureus* internalization ([@bib82]). These observations, along with evidence that butyrate is not toxic to *S. aureus,* indicate that butyrate-mediated upregulation of HDP rather than butyrate itself is likely responsible for inhibition of *S. aureus* internalization ([@bib82], [@bib2]). However, it is important to note that stimulation of cells with butyrate and *S. aureus* also produced a 10-fold induction in nitric oxide ([@bib82]), suggesting that butyrate enhances bovine mammary gland defense by triggering both oxidative and non-oxidative mechanisms. Nevertheless, there is no increase in nitric oxide production in bovine mammary epithelial cells in response to 1 mmol/L sodium propionate or hexanoate ([@bib2]).

4.4. Swine {#sec4.4}
----------

In porcine IPEC-J2 intestinal epithelial cells and 3D4/2 or 3D4/31 lung alveolar macrophage cells, 2 to 8 mmol/L butyrate induces the expression of multiple, but not all, porcine β-defensins and cathelicidins (PG1-5) in a time- and dose-dependent manner ([@bib120], [@bib140]). However, PBD1 fails to be induced in any cell type. Moreover, the magnitude of induction and optimal butyrate dose vary among different genes and cell types. For example, PBD2 is the most highly induced HDP in IPEC-J2 cells with an approximately 80-fold increase in response to 8 mmol/L butyrate ([@bib149]), but shows only a marginal induction in 3D4/31 cells at all doses applied, while PBD3 displays an impressive 200-fold induction when stimulated with 8 mmol/L butyrate ([@bib149]).

As in humans and chickens, the hydrocarbon chain length of free fatty acids is also correlated with their ability to induce HDP expression in swine. All free fatty acids with a hydrocarbon chain length of 1 to 18 are capable of inducing PBD2, PBD3, and EP2C in a dose-dependent manner ([@bib149]). However, free fatty acids with a length of four carbons or less display an increased magnitude of HDP induction with an increasing carbon number, while a length-dependent decrease in HDP induction was observed for the carbon length greater than four ([@bib149]). Additionally, 2 g/kg sodium butyrate shows the ability to alleviate the clinical symptoms of *E. coli* O157:H7 infection in weanling pigs and enhance bacterial clearance in 3D4/2 cells, which is associated with an increased HDP expression ([@bib140]).

5. Vitamin D {#sec5}
============

5.1. Physiological functions of vitamin D {#sec5.1}
-----------------------------------------

Vitamin D is taken up directly from the diet or converted naturally from cholesterol in the skin in response to ultraviolet-B sunlight exposure. Biologically active 1α,25-dihydroxyvitamin D~3~ (1,25D~3~) is formed by activation of pre-vitamin D~3~ consecutively in the liver and kidney through 2 hydroxylation reactions ([@bib121], [@bib24]). 1,25D~3~ exerts its biological activities through binding to the vitamin D receptor (VDR), which forms a heterodimer with retinoid X receptors to regulate the expression of a large group of genes ([@bib121], [@bib24]). Vitamin D is well-known to be critical in calcium homeostasis and bone mineralization. Accumulating evidence has suggested a number of extra-skeletal effects on innate immunity and cancer inhibition ([@bib121], [@bib24]). First, vitamin D exerts anti-inflammatory effects by reducing the expression of pro-inflammatory cytokines such as *IL-1β, 1L-6, IL-8, CCL2, TNF-α*, and *IFN-γ* after pathogenic challenge ([@bib55], [@bib21], [@bib153]). Vitamin D is also capable of promoting macrophage activation and phagocytosis, while steering monocyte differentiation toward macrophages rather than dendritic cells ([@bib142], [@bib156], [@bib36]).

5.2. Vitamin D in growth performance and disease prevention {#sec5.2}
-----------------------------------------------------------

National Research Council (NRC) recommends dietary inclusion of vitamin D at 200, 150 to 220, and 250 IU/kg for broilers, growing pigs, beef cattle, respectively, where 1 IU is equivalent to 25 ng vitamin D~3~. The effects of vitamin D on growth and disease prevention in livestock has not been well studied. Inclusion of vitamin D at 5,000 IU/kg in piglet diets improved intestinal morphology and the serum concentration of IFN-β, while decreasing IL-2 and IL-6 serum concentrations, in the context of porcine rotavirus infection ([@bib154]). As a result, growth performance (average daily gain and average daily feed intake) of rotavirus-challenged piglets was improved in response to 5,000 IU/kg of vitamin D ([@bib154]). Similarly in dairy cattle, intramammary injection of 100 μg of 25-hydroxyvitamin D~3~ twice daily for 5 days has been shown to increase bacterial clearance and decrease mastitis severity, milk somatic cell counts, and body temperature, while restoring feed intake and loss of milk production in a mastitis model ([@bib63]).

6. Impact of vitamin D on HDP expression {#sec6}
========================================

6.1. Humans {#sec6.1}
-----------

Besides its role in calcium homeostasis and anti-inflammation, vitamin D was recently shown to have a strong ability to induce *LL-37* and *HBD-2* expression in multiple human cell lines and primary cell cultures ([@bib131], [@bib34], [@bib45], [@bib54], [@bib60], [@bib66]). Induction of LL-37 is shown to be critical in vitamin D-mediated protection against *Mycobacterium tuberculosis* ([@bib64]). Replication of rhinovirus is suppressed in primary bronchial epithelial cells pretreated with vitamin D, which is likely due to induction of LL-37 ([@bib107]). Consistently, a positive correlation between serum concentrations of 25-hydroxyvitamin D~3~ and LL-37 has been observed ([@bib49], [@bib25]). Furthermore, oral supplementation of vitamin D increases plasma concentrations of LL-37 in both healthy ([@bib88]) and mechanically ventilated, critically ill individuals ([@bib43]). Vitamin D supplementation also promotes the anti-mycobacterial activity of macrophages in type 2 diabetes patients ([@bib65]). It is noted that vitamin D-mediated induction of cathelicidin is not conserved in rodents, since murine cathelicidin gene lacks a vitamin D response element in the promoter ([@bib23]); however, cathelicidins and defensins can still be induced by vitamin D in livestock animals as detailed below.

6.2. Poultry {#sec6.2}
------------

In poultry, 20 and 200 ng/mL (equivalent to 48 and 480 nmol/L) vitamin D~3~ has been shown to induce AvBD3, AvBD6, and AvBD9 in chicken embryonic intestinal epithelial cells, while AvBD1, AvBD6, and AvBD9 were induced in a dose-dependent manner in primary monocytes ([@bib151]). Consistently, CATH-1 and CATH-B1 were dose-dependently induced by dietary vitamin D in the spleen of chickens and that induction was further enhanced by low calcium and phosphorus in the diet, although CATH-3 was suppressed ([@bib97]). However, only CATH-1 was significantly induced in response to 9,800 IU/kg of vitamin D~3~ supplementation in the bursa of Fabricius, while no cathelicidins were enhanced by any of the treatments in peripheral blood mononuclear cells ([@bib97]). Intraperitoneal injection of chickens with 5,000 IU/kg of body weight of vitamin D failed to upregulate *HDP* expression in the chicken intestinal tract, but multiple HDP were synergistically induced in response to both vitamin D and LPS ([@bib67]).

6.3. Cattle {#sec6.3}
-----------

Cholecalciferol, a 1,25D~3~ precursor, induces several β-defensins such as lingual antimicrobial peptide and bovine β-defensin 1 in bovine mammary epithelial cells, and further inhibits *S. aureus* internalization at 50 nmol/L ([@bib124]). *S. aureus* also induces all HDP investigated, but cholecalciferol inhibits the induction of HDP except for bovine neutrophil β-defensins (BNBD)10 ([@bib124]). Vitamin D up-regulates the expression of multiple BNBD including *BNBD3, BNBD4, BNBD6, BNBD7*, and *BNBD10* in both a time- and dose-dependent manner in bovine monocytes with 1 nmol/L observed as the optimal dose ([@bib75]). However, 4 ng/mL vitamin D alone fails to induce the expression of bovine cathelicidins 4-6 in monocytes ([@bib81]). Expression of β-defensins is further increased when monocytes are stimulated with both 1 nmol/L cholecalciferol and LPS ([@bib75]). Intramammary administration of 10 μg of 1,25D~3~ every 12 h for 2 days results in an induction of BNBD7 in mammary somatic cells and mammary macrophage cells ([@bib75], [@bib76]). Along with BNBD7, repeated injection of 1,25D~3~ in bovine mammary glands with subclinical mastitis also leads to an induction of BNBD4 ([@bib76]).

6.4. Swine {#sec6.4}
----------

Very little work has been done to elucidate the effect of vitamin D on *HDP* expression in pigs. However, porcine cathelicidin PR-39 is induced and viral replication reduced in response to 0.5 μmol/L 25-hydroxyvitamin D~3~ in porcine IPEC-J2 and 5,000 IU/kg in jejunal and ileal epithelial cells of piglets challenged with rotavirus ([@bib127])*.* Additionally, stimulation of IPEC-J2 cells with 0.5 μmol/L 25-hydroxyvitamin D~3~ followed by rotavirus infection increases the expression of two other porcine cathelicidins (PG1-5 and PMAP23) ([@bib127]). However, it should be noted that both antiviral RIG-I ([@bib154]) and autophagy signaling pathways ([@bib127]) appear to be activated by vitamin D treatment as well; therefore, relative contribution of vitamin D-mediated HDP synthesis in limiting rotavirus infection remains to be investigated.

7. Signaling mechanisms in HDP induction by butyrate and vitamin D {#sec7}
==================================================================

7.1. Butyrate induces *HDP* expression through histone acetylation and mitogen-activated protein kinase (MAPK) signaling pathways {#sec7.1}
---------------------------------------------------------------------------------------------------------------------------------

Histone acetylation is an important chromatin epigenetic modification mechanism that regulates gene transcription. Histone deacetylases (HDAC) function by removing acetyl groups from histone proteins causing chromatin condensation and reduced binding of transcription factors to the gene promoter and subsequent gene transcription, whereas the opposite is true with histone acetylases (HAT) ([@bib12]). The balanced action between HDAC and HAT is critical in controlling the transcription of a large group of genes. HDAC inhibitors act by suppressing HDAC enzymes, thereby facilitating histone acetylation and gene transcription ([@bib108]). In fact, transcription of as many as 7% to 10% of human genes is affected by HDAC inhibition ([@bib32]).

Butyrate is a well-known natural HDAC inhibitor ([@bib94], [@bib19]) and has been shown to induce *HDP* gene expression primarily by acting as a HDAC inhibitor ([@bib143]) ([Fig. 1](#fig1){ref-type="fig"}). Butyrate-mediated HDP induction is associated with increased acetylation of histone proteins in human EBC-1 lung epithelial cells ([@bib56]), HT-29 colonic carcinoma cells, HepG2 hepatocellular carcinoma cells, and 23132/87 gastric carcinoma cells ([@bib103]), as well as chicken HD11 macrophage cells ([@bib119]) and porcine 3D4/2 macrophage cells ([@bib140]). Consistently, structurally unrelated, but functionally similar HDAC inhibitors such as trichostatin A ([@bib52]), sulforaphane ([@bib110]), resveratrol and its precursor or analog ([@bib83], [@bib91], [@bib41]), curcumin ([@bib40]), apicidin ([@bib52]), and MS-275/entinostat ([@bib52], [@bib78]) are all capable of inducing *HDP* expression. However, the HDAC inhibitory activity of an HDAC inhibitor does not always directly correlate with its ability to induce *HDP* gene expression. For example, a potent HDAC inhibitor such as trichostatin A is less efficient in HDP induction than a weak HDAC inhibitor such as butyrate ([@bib103]). Secondly, high concentrations of a HDAC inhibitor, which normally results in stronger HDAC inhibition, often show reduced HDP induction ([@bib103], [@bib118], [@bib119]). These results imply the involvement of other regulatory mechanisms beyond epigenetic control. In accordance with this, the MAPK and VDR pathways have been implicated in the upregulation of HDP by butyrate ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1**Induction of human cathelicidin *LL-37* gene expression by butyrate and vitamin D.** Butyrate induces *LL-37* expression primarily by acting as a histone deacetylases (HDAC) inhibitor and by activation of mitogen-activated protein kinase (MAPK) signaling cascades, whereas 1α,25-dihydroxyvitamin D~3~ (1,25D~3~) enhances *LL-37* expression by interacting with vitamin D receptor (VDR), which subsequently dimerizes with retinoid X receptor (RXR) and binds to the vitamin D response element (VDRE) site on the *LL-37* gene promoter. Inhibition of HDAC by butyrate will lead to hyper-acetylation of histones, relaxation of chromatin, and subsequent *LL-37* gene expression. Butyrate-mediated *LL-37* expression involves activator protein 1 (AP-1) activation by MAPK and also requires VDR, while vitamin D enhances *LL-37* expression through VDR/ retinoid X receptor (RXR) dimerization and subsequent recruitment of transcriptional coactivators such as steroid receptor coactivator-3 (SRC-3) and CBP/p300, which have the histone acetylase (HAT) activity resulting in hyper-acetylation of histones and subsequent *LL-37* expression. CCAAT-enhancer-binding protein α (C/EBPα) and Brahma, which is a component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex, are also critically involved in vitamin D induction of LL-37. Vitamin D amplifies its own effects by inducing C/EBPα. Butyrate and vitamin D synergize with each other mainly by cooperatively acting on chromatin remodeling and histone acetylation. Butyrate also transcriptionally induces *VDR* expression. Activation of MAPK signaling cascades further exerts profound influence on C/EBPα and components of chromatin remodeling complex and histone acetylation enzymes; however, whether and which butyrate receptors are involved in MAPK activation remain elusive. Ac = acetyl group; CBP = cyclic AMP-response element-binding protein (CREB) binding protein.

Mitogen-activated protein kinase signaling cascades are comprised of three major canonical pathways including the extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and p38 kinase pathways ([@bib135], [@bib53], [@bib96]), with the specific pathway involved in butyrate regulation varying by cell type and gene. Inhibition of the ERK1/2 pathway using specific inhibitors has been shown to consistently attenuate butyrate-mediated induction of LL-37 in human lung epithelial cells ([@bib56]) and several colonic cell lines ([@bib105], [@bib103], [@bib111]). However, suppression of the ERK1/2 pathway plays no role in butyrate-induced bovine *HDP* expression in mammary cells ([@bib1]) and surprisingly further potentiates butyrate induction of AvBD9 in chicken HD11 macrophage ([@bib120]). Similarly, the ERK1/2 pathway is also involved in HDP induction by butyrate derivatives such as 4-phenylbutyrate ([@bib117]). In contrast, the p38 pathway is essential in butyrate-mediated HDP induction in human lung and Caco-2 colonic epithelial cells ([@bib56], [@bib111]), bovine mammary cells ([@bib1]), and chicken HD11 cells ([@bib120]), but has a minimal role in LL-37 induction in human SW620 colonic epithelial cells ([@bib105]). Involvement of JNK signaling in butyrate-induced *HDP* expression has been shown in human lung cells ([@bib56]) and chicken HD11 cells ([@bib120]), but appears to be dispensable in bovine mammary cells ([@bib1]).

The transcription factor, AP-1, is regulated by all three canonical MAPK signaling pathways ([@bib135], [@bib53]) and putative binding sites for AP-1 have been found in the LL-37 promoter ([@bib56]) and the promoters of bovine HDP ([@bib1]). In both cases, butyrate treatment was found to activate AP-1, indicating its involvement in the regulation of *HDP* expression. In Caco-2 cells, VDR inhibition significantly decreased LL-37 induction by butyrate or 4-phenylbutyrate ([@bib111]), suggesting that VDR is involved in the induction of HDP by butyrate. As the p38 pathway is required for butyrate induction of the VDR and Caco-2 cell differentiation ([@bib18]), it is possible that butyrate may induce LL-37 through p38 phosphorylation. Butyrate is also known to achieve some of its biological effects through interacting with its major receptors such as FFA2/GPR43 and FFA3/GPR41 ([@bib6]); however, the role of these receptors in butyrate-mediated HDP induction remains to be determined. It is also noted that PU.1 ([@bib125]) and TGF-β1 receptor kinase ([@bib111]), but not peroxisome proliferators-activated receptors γ (PPARγ) ([@bib111]), have been implicated in butyrate-mediated up-regulation of LL-37 in human HT-29 or Caco-2 cells.

7.2. Vitamin D induces HDP expression via VDR {#sec7.2}
---------------------------------------------

Vitamin D is known to elicit its effects through binding and activation of VDR, which subsequently binds to the vitamin D response element (VDRE) in the promoter of target genes to increase transcription ([@bib121]). Indeed, inhibition of the VDR or deletion of the VDRE diminishes LL-37 induction in response to vitamin D in human keratinocytes ([@bib105], [@bib102]), bronchial epithelial cells ([@bib145]), and pulmonary epithelial cells ([@bib20]) ([Fig. 1](#fig1){ref-type="fig"}). While a VDRE is present in the promoter of LL-37 and HBD-2, bovine β-defensins may not be directly targeted by vitamin D, as cycloheximide, a protein translation inhibitor, can block vitamin D-mediated β-defensin induction in bovine monocytes ([@bib75]). In addition to VDR, [@bib102] found that inhibition of the ERK1/2 pathway also significantly reduced LL-37 induction by vitamin D, indicating the involvement of the ERK1/2 pathway in regulation of the VDR.

Furthermore, [@bib20] found that vitamin D increases the CCAAT/enhancer-binding protein α (C/EBPα) synthesis, which subsequently induces *LL-37* expression in pulmonary epithelial cells. Chromatin immunoprecipitation assays in these cells found that vitamin D recruits C/EBPα and VDR to their respective binding sites in the LL-37 promoter and that C/EBPα binding is associated with recruitment of Brahma, an ATPase of the SWI/SNF chromatin remodeling complex ([@bib20]). Moreover, inhibition of SRC3, a major transcriptional cofactor of VDR in keratinocytes, attenuated vitamin D induction of LL-37, indicating its role in the HDP response as well ([@bib105]).

7.3. Butyrate and vitamin D signaling pathways converge to synergistically induce HDP {#sec7.3}
-------------------------------------------------------------------------------------

In addition to inducing HDP individually, concomitant stimulation with butyrate and vitamin D has been shown to produce a synergistic induction of *HDP* gene transcription in multiple cell lines ([Fig. 1](#fig1){ref-type="fig"}). In human keratinocytes, butyrate alone has a minimum effect on *LL-37* expression, but in combination with vitamin D leads to a synergistic induction ([@bib104]). The synergy is associated with increased histone acetylation and activation of SRC3 and VDR ([@bib104]). It is not surprising that 4-phenylbutyrate also synergizes with vitamin D in LL-37 induction in human bronchial epithelial cells ([@bib117], [@bib58]) and macrophages ([@bib93]), and the VDR is critically involved in the synergy ([@bib117], [@bib58]). However, additional studies are warranted to identify other mechanisms such as the involvement of the MAPK pathways in the synergy between butyrate and vitamin D.

8. Conclusions {#sec8}
==============

The discovery of links between subtherapeutic antibiotic use in livestock animals and antibiotic resistance has created a shift in public opinion and governmental policy regarding the use of antibiotics in livestock production. In order to maintain animal health and productivity, effective and reliable antibiotic alternatives are needed. Modulation of endogenous HDP synthesis by dietary compounds such as butyrate and vitamin D has emerged as a potentially viable alternative to fill this need. It is noted that, although butyrate is produced endogenously through bacterial fermentation to the millimolar concentrations in the rumen, cecum or colon, which should be sufficient in HDP induction, butyrate production in the small intestine is well below the HDP-inducing concentrations. Dietary supplementation of protected or unprotected butyrate at 1 to 2 g/kg often provides benefits to animals, particularly in the context of stress or infection. Similarly, although vitamin D~3~ is routinely included in the animal diet to 150 to 250 IU/kg, much higher doses (e.g., 2,000 to 5,000 IU/kg) are needed in order to elicit a HDP-inducing and health-promoting effect. It has become clear that the molecular mechanisms involved in butyrate- and vitamin D-mediated HDP synthesis vary by gene, cell type and animal species, but are primarily accomplished through chromatin remodeling, histone acetylation, and activation of the MAPK signaling pathways, leading to activation of transcription factors such as VDR and AP-1. Synergistic induction of HDP synthesis by butyrate and vitamin D appears to occur through the cooperative activation of chromatin remodeling complex and HAT and suppression of HDAC, resulting in hyper-acetylated histones and much relaxed chromatin for subsequent enhancement in gene transcription. Overall, these HDP-inducing compounds, particularly their combinations, have the ability to augment animal innate immunity and protect animals from diseases demonstrates their potential for further development as novel alternatives to antibiotics.
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